{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-24-000128","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.122416+00:00","generated_at":"2026-05-30T08:19:59.721041+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arvinas Q3 2024 revenue $102.4M; cash $1.12B; VERITAC-2 data on track 4Q24/1Q25","bullets":["Q3 revenue $102.4M (vs $34.6M YoY) mainly from Novartis license $76.7M.","Cash and marketable securities $1.12B; sufficient to fund operations into 2027.","R&D $86.9M; G&A $75.8M incl. $43.4M lease termination loss.","VERITAC-2 Phase 3 topline data on track for 4Q24/1Q25; abemaciclib data at SABCS Dec 2024.","ARV-102 MAD portion started; KRAS G12D IND filing expected 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-24-000128","json":"https://secwatch.observer/filing/0001655759-24-000128.json","markdown":"https://secwatch.observer/filing/0001655759-24-000128.md","text":"https://secwatch.observer/filing/0001655759-24-000128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000128/0001655759-24-000128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000128/arvn-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:19:59.721041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}